APLS
Apellis Pharmaceuticals Inc

3,682
Mkt Cap
$2.68B
Volume
1.87M
52W High
$30.48
52W Low
$16.10
PE Ratio
169.72
APLS Fundamentals
Price
$20.96
Prev Close
$21.64
Open
$21.30
50D MA
$23.15
Beta
1.02
Avg. Volume
4.02M
EPS (Annual)
$0.1724
P/B
7.17
Rev/Employee
$1.36M
$3,268.56
Loading...
Loading...
News
all
press releases
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen cut Apellis Pharmaceuticals from a "buy" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Optimistic Outlook for APLS Earnings
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Apellis Pharmaceuticals in a report released on...
MarketBeat·2d ago
News Placeholder
Analysts Issue Forecasts for APLS FY2030 Earnings
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report...
MarketBeat·3d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $44.00 by Analysts at Citigroup
Citigroup decreased their price target on shares of Apellis Pharmaceuticals from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday...
MarketBeat·4d ago
News Placeholder
Royal Bank Of Canada Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00
Royal Bank Of Canada cut their target price on Apellis Pharmaceuticals from $22.00 to $21.00 and set a "sector perform" rating on the stock in a research report on Wednesday...
MarketBeat·4d ago
News Placeholder
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Zacks·4d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $18.00 at Wedbush
Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a "neutral" rating for the company in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright boosted their price target on Apellis Pharmaceuticals from $45.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down - Time to Sell?
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down - Time to Sell...
MarketBeat·5d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +219.14% and +2.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
<
1
2
...
>

Latest APLS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.